OMEROS CORPORATION

Omeros Corporation (biotechnology/pharmaceuticals) discloses in 10-K Item 1C that it maintains a cybersecurity risk management program, including technical, physical, and organizational measures, third-party vendor risk assessments, and employee training (including simulated phishing). The company explicitly states it is not aware of any specific cybersecurity threats that have materially affected or are reasonably likely to materially affect its business, strategy, results of operations, or financial condition. No specific incidents, data breaches, or material impacts are reported.